Survival Differences of Localized Papillary Renal Cell Carcinoma in African Americans vs. European Americans

Bibliographic Data

ID19228367
AuthorsMaximilian Filzmayer (0009-0005-5715-9965, Goethe University Frankfurt, corresponding author), Federico Polverino (Université de Montréal), Michele Petix (University of Milan), Leonardo Quarta (Vita-Salute San Raffaele University), Filippo Orlandi (University of Modena and Reggio Emilia), Jordan A Goyal (0009-0006-4609-8981, Université de Montréal), Nicola Longo (0009-0009-3394-0596, University of Naples Federico II), Luca Carmignani (University of Milan), Alberto Briganti (0000-0002-2178-0494, Vita-Salute San Raffaele University), Salvatore Micali (0000-0003-2121-1897, University of Modena and Reggio Emilia), Shahrokh F Shariat (0000-0002-6627-6179, Al-Ahliyya Amman University), Clara Humke (Goethe University Frankfurt), Miriam Traumann (Goethe University Frankfurt), Miriam I Traumann, Mike Wenzel (Goethe University Frankfurt), Fred Saad (0000-0003-3639-4753, Université de Montréal), Felix K H Chun (Goethe University Frankfurt), Pierre I Karakiewicz (0000-0003-1354-5854, Université de Montréal)
Year2026
Publication date2026-06-13
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueJournal of Racial and Ethnic Health Disparities (JOURNAL)
Journal identifiersISSN: 2196-8837 • E-ISSN: 2197-3792
PublisherSpringer Science+Business Media (PUBLISHER • DE)
DOI10.1007/s40615-026-03038-3
PMID42288708
OpenAlexW7164655366
LanguageEN
References cited31

PURPOSE: African Americans exhibit a higher prevalence of papillary renal cell carcinoma (pRCC). We assessed overall and cause-specific survival differences between African Americans and European Americans with surgically treated localized pRCC. METHODS: African Americans and European Americans who underwent nephrectomy for T1b-2 N0 M0 pRCC were identified within the Surveillance, Epidemiology and End Results database (2004-2021). Propensity score matching (PSM) was applied, and multivariable Cox regression as well as competing-risks regression (CRR) models were fitted. RESULTS: Of 3,707 patients, 1,345 (36.3%) were African Americans and 2,362 (63.7%) were European Americans. After PSM, no significant differences in socioeconomic, demographic, or tumor-specific characteristics remained between the two groups. Overall survival (OS) rates at 120 months after nephrectomy were 59.4% in African Americans vs. 66.9% in European Americans (p = 0.026). In multivariable Cox regression models, the African American group was associated with higher overall mortality (hazard ratio [HR] 1.24, 95% confidence interval [CI]: 1.05-1.47, p = 0.013). Other-cause mortality (OCM) at 120 months after nephrectomy was higher in African Americans (29.0% vs. 22.2%), while cancer-specific mortality (CSM) did not differ (11.0% vs. 10.3%) between the two populations. Finally, in multivariable CRR models, the African American group predicted higher OCM (HR 1.33, 95% CI: 1.08-1.64, p = 0.007), but did not affect CSM (HR 1.06, 95% CI: 0.77-1.45, p = 0.7). CONCLUSION: In surgically treated localized pRCC, OS in African American patients is lower compared to European American patients. This difference in OS is not explained by CSM. Instead, it reflects significantly higher OCM in African American patients

African american · Confidence interval · Nephrectomy · Papillary renal cell carcinomas · Propensity score matching · Proportional hazards model · Renal cell carcinoma · Surveillance, Epidemiology, and End Results · Bladder and Urothelial Cancer Treatments · Epidemiology · Multiple and Secondary Primary Cancers · Renal cell carcinoma treatment

Tools

Open DOIOpen Access